Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.

  • Axsome Therapeutics focuses on CNS disorders with Auvelity, Sunosi, and Symbravo pipeline drugs.
  • Moderna's revenue declines due to COVID-19 vaccine demand drop and competition.
  • Axsome shows positive revenue trends, while Moderna experiences volatility.

More from Wednesday 28 October →